Coya Therapeutics Q3 2026 Earnings Date & Estimates

Coya Therapeutics (NASDAQ:COYA) is a clinical-stage biotechnology company focused on developing therapies that regulate neuroinflammation and support immune-system function. The company’s research centers on regulatory T cells, or Tregs, immune cells that help control excessive inflammatory responses. Coya is developing treatments intended for neurodegenerative diseases in which inflammation may contribute to disease progression.

The company’s lead programs include COYA 101, an autologous Treg cell therapy in which a patient’s cells are collected, expanded and activated outside the body, and then administered as a potential treatment for amyotrophic lateral sclerosis (ALS). Coya is also developing combination approaches, including COYA 302, which is designed to combine Treg-based therapy with immune-modulating treatment. The company’s broader pipeline is intended to address additional neurodegenerative and inflammatory conditions.

Coya Therapeutics is headquartered in Houston, Texas, and conducts its development activities through clinical research and collaborations with academic and medical institutions. Its programs remain investigational and are subject to clinical testing and regulatory review.